Clinical Trial Update: Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating mycophenolate mofetil for systemic sclerosis with subclinical interstitial lung disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Systemic Sclerosis With Lung Involvement, Systemic Sclerosis | Phase 2 | Status: RECRUITING